December 22, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

Registration is OPEN for #NRG2026!

Registration is OPEN for the NRG 2026 Winter Meeting

Join us at the Hilton San Francisco Union Square for the NRG 2026 Winter Meeting. The meeting will be held in-person, January 22-24, 2026, with select virtual sessions being held January 12-16, and January 20, 2026. Register by January 2, 2026 to avoid the late registration fee!

NOTE: MDs and DOs who attend the meeting in-person and register for both the NRG Meeting and Winter Symposium will receive a bundle discount for a total fee of $325.00 USD. ($140.00 USD savings). Please use the discount code IPCOMBOMTGSYM.



More information | Agenda | Register

Winter 2026 Symposium – Theranostics: Precision Imaging Meets Targeted Therapy

Join us on in San Francisco, CA on Thursday, January 22, 2026 from 8am-12pm PT. The session will also be available virtually. This symposium will provide a comprehensive look at theranostics and radiopharmaceutical therapy. The program will begin with an introduction to the scientific foundations of radiopharmaceuticals, outlining how these agents differ from external beam radiation, and the practical considerations of imaging, dosimetry, and safe delivery. Participants will gain insight into the operational, regulatory, and infrastructural requirements needed to build a successful theranostics program within their institution.

Program Chair: Denise Fabian, MD and Co-Chairs: Charles Kunos, MD/PhD; Elise Kohn, MD

More information | Register

Announcing the #NRG2026 Investigator & Career Development Committee Educational Session!

This year’s program explores protocol development from every angle—early-career investigators shaping their first studies, experienced leaders refining best practices, NRG operations guiding feasibility, experts addressing health care access, and insights from a disease site committee leader. Additional information is included on the session flyer.

Communications & Digital Engagement Workshop

The NRG Oncology Communications Committee is pleased to announce our Communications & Digital Engagement (CDE) Workshop as part of #NRG2026. The workshop, being held as a virtual session, is scheduled for Tuesday, January 20, 2026, 1-2pm ET (10-11am PT). Drs. Kristin Higgins and Miriam Knoll, members of the NRG Oncology Communications Committee, are the session chairs. The speakers include Dr. Nina Sanford, GI radiation oncologist at UT Southwestern Medical Center and chair of the NRG Pancreas GI Subsite Working Group, who will discuss how she uses social media to drive scientific dialogue; and Jason Tharp, a member of NRG’s Patient Advocate Committee, a brain cancer survivor turned keynote speaker, author of 23+ books, and founder of the Beyond Hope Project. Additional information is included on the session flyer.

NRG Scientific Session - Friday, January 23, 3-4:30pm PT

Join us for the #NRG2026 Scientific Session featuring updates on antibody–drug conjugates and novel approaches in breast and ovarian cancer, followed by highlights from top recent NRG abstracts presented at national meetings. Details are included on the session flyer.

NCORP Bootcamp at #NRG2026

Join NRG Oncology NCORP leaders for the NCORP 2026 Bootcamp designed to increase understanding of the NRG Oncology NCORP Research Base and NCORP Community Sites:

• Dr. Lisa Kachnic will provide an overview of the functions and strategic role of an NCORP Research Base.
• Dr. Carolyn Muller, PI of the University of New Mexico NCORP, will share insights from the field describing the operations and impact of an NCORP community site.

A panel discussion will focus on developing and enrolling to NCORP trials, with perspectives from both.

All attendees are invited to participate in interactive breakout groups focused on:

• Patient advocate engagement - To help investigators strengthen their NCORP concepts by integrating patient advocate perspectives early in development ensuring trials are understandable, feasible, and meaningful to participants.
• CPC, HCA and PCOR committees – learn more about NCORP concept development, collaboration with NRG committees, and integration of health care access throughout NRG trial development.
• Developing a framework for Advanced Practice Providers within NRG Oncology.

The #NRG2026 Bootcamp is being held on Thursday, January 22, 2026. Additional information is included on the session flyer.

NRG Protocol Support Committee – Continuing Education Sessions

Please join the Protocol Support Committee for their upcoming Continuing Education sessions being held during #NRG2026 in San Francisco on Thursday, January 22, 2026. The Continuing Education Session for Nurse/CRAs on Thursday morning will be held virtually and in-person and is for both seasoned and new research staff. The monthly Discuss With Us session is being held in-person only and will cover topics including Onboarding & Retention, Biospecimen Collection & QOLs, and more! The Protocol Spotlight session on Thursday afternoon will be held in-person and virtually and will discuss the following studies – NRG-GU015, NRG-HN014, and NRG-CC014. Please refer to the posted agendas (login required) and flyers for more details about the PSC programing offered during #NRG2026. These sessions have been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

AMENDMENTS

GENITOURINARY

NRG-GU010: Amendment 3; dated November 14, 2025 (posted on CTSU)

NRG-GU013: Amendment 1; dated July 24, 2025, and Amendment 2; dated December 10, 2025 (posted on CTSU)

GYNECOLOGIC

NRG-GY031: Action Letter for ZEN003694 dated December 16, 2025; Amendment 3; version date: November 3, 2025 (posted on CTSU and NRG Oncology)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only (posted on CTSU)

2. BIOSPECIMEN BANK

Important Update: Kit Shipments to Sites in Canada

The NRG Oncology Biospecimen Bank - Columbus thought the issues with shipments of kits had been resolved, but many kits continue to be delayed or rejected at customs. We apologize for the inconvenience. While our institution continues to work on resolving this issue, we must once again ask sites in Canada to provide their FedEx account number to cover duties and taxes at the time they order kits. Please note this is a temporary measure being instituted to allow the kits to pass through customs. We will provide an update once access to the CARM portal has been established. Please direct questions to:

NRG Biospecimen Bank - Columbus

• Phone: 614-722-2865
• Email: BPCBank@nationwidechildrens.org

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011: The central lab, NYU Langone, will be closed on Thursday December 25, 2025 and Thursday January 1, 2026. Please plan tissue shipments accordingly.

4. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Clinical research professionals can sign up for NRG Oncology Weekly Broadcasts to receive monthly FORTE Fridays updates directly to your inbox (click here).

NRG-CC013: Treatment interruptions of radiation, cisplatin, and/or BMX-001 for non-medical reasons (holidays, vacations, weather, unexpected machine down time, etc) are at the treating investigator’s discretion and should follow local policy/practice. If the protocol therapy cannot be administered according to schedule, the local PI should be involved in decisions regarding rescheduling. Interruptions should be documented in the treatment/research record and include the reason and duration. Please see the memo posted on CTSU.

5. GASTROINTESTINAL

NRG-GI011: The following documents are available on CTSU:

• Study Memorandum dated November 14, 2025, regarding a clarification on prior radiation treatment Updated Training Slides, version date November 17, 2025
• Updated Training Slides, version date November 17, 2025

6. GENITOURINARY

NRG-GU011: Please see Study Memorandum dated November 17, 2025 (posted on CTSU), regarding shipment timelines during the holidays. To avoid delays, submit shipment requests as soon as possible to support subject visits scheduled between November 10, 2025, and January 10, 2026.

7. GYNECOLOGIC

NRG-GY026: Accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY037 requires blocks to be submitted, but the study team recognizes variations in site operating procedures to release blocks. Please refer to the Letter to Pathologists in the Biospecimen Collection and Submission Manual. If your site is experiencing any issues with this requirement, please contact the study team as we can work with sites on a case-by-case basis to ensure patients have an opportunity to participate in this trial.

8. HEAD & NECK

NRG-HN004: A summary of research results is available on the NRG Patient Study Materials Web Page and the CTSU website. Sites, please share the summary of research results with study participants.

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

RTOG 1216: The Ferris Laboratory will not be accepting samples (fresh heparin and Streck blood tubes) from December 24, 2025, through January 1, 2026. The lab will begin receiving samples on January 2, 2026. Please plan your appointments accordingly to avoid any delays or compromised samples. Thank you for your attention and cooperation.

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GI011, NRG-GI012, NRG-GU015, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for January 14, 2026.

Safety and Investigator Brochure (IB) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. Winter Holiday Closure Information

Winter holiday closure information for the NRG Oncology Operations Offices, Statistics and Data Management Centers (SDMCs), Biospecimen Banks, and McKesson's Clinical Research Services is posted on the CTSU website (under LPO updates).

2. NRG Oncology Currents Newsletter

The December edition of the NRG Currents newsletter is now available! This issue features highlights for the upcoming NRG Winter meeting, leadership announcements, new podcast episodes, plus much more. Check it out here  

3. NRG Oncology Current Committee Leadership Openings

•  Vice Chair, Ancillary Projects Committee 

Applications DUE January 7, 2026 - Read more & How to Apply



•  Vice Chair, Protocol Operations Management Committee 

Applications DUE January 7, 2026 - Read more & How to Apply

 NRG Oncology Current Committee Openings

• Patient Advocate Committee (PAC) 

Applications DUE January 15, 2026 - Read more & How to Apply

4. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles that appeared during the previous week, as well as abstracts accepted for presentation at the Society for Gynecologic Oncology’s Annual Meeting on Women’s Cancer.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED ABSTRACTS

Cosgrove, Casey M; Coombs, Kevin; Darcy, Kathleen M; Miller, Austin; Deng, Wei; Ramirez, Nilsa C; Felix, Ashley S; Lankes, Heather A; Hagemann, Ian S; Quick, Allison; Backes, Floor J; Liu, Ying; Bae-Jump, Victoria L; Leslie, Kimberly K; Miller, David S; Goodfellow, Paul J; Mutch, David G; Powell, Matthew: Race-Associated Genomic and Transcriptomic Features and Outcomes in High-Risk Endometrial Cancer: A Cancer Moonshot and NRG Oncology/GOG-210 Study. SGO (Society of Gynecologic Oncology). 4/10/2026; Focused forum oral presentation.

Erickson, Britt K; Enserro, Danielle M; Lankes, Heather A; Dockery, Lauren E; Oliver, Matthew T; Blank, Stephanie V; Micaily, Ida; Press, Joshua Z; Castellano, Tara; Girda, Eugenia; Growdon, Whitfield; Santin, Alessandro; Deery, Amy; Weinberg, Lori; Havrilesky, Laura J; Aghajanian, Carol A; Nickles Fader, Amanda; Powell, Matthew A: Phase III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial carcinoma (NRG-GY026). SGO (Society of Gynecologic Oncology). 4/11/2026; Poster presentation.

Hopp, Elizabeth; Enserro, Danielle M; Campos, Susana; Chitiyov, Viola; Huang, Gloria S; Lankes, Heather A; Crane, Erin; Hoekstra, Anna; Siedel, Jean; Richardson, Debra; Aghajanian, Carol A; Rader, Janet S: A phase II study of androgen receptor (AR) inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor. SGO (Society of Gynecologic Oncology). 4/13/2026; Focused forum oral presentation.

PUBLISHED ARTICLES

Ku AT, Shankavaram U, Trostel SY, Zhang H, Kartal S, Sater HA, Harmon SA, Carrabba NV, Liu Y, Ryu H, Proudfoot JA, Hong BH, Wood BJ, Pinto PA, Choyke PL, Roach M, Sandler HM, Pugh SL, Zeitzer KL, Mendez LC, Kapadia NS, Hall WA, Desai AB, Stoyanova RS, Pollack A, Davicioni E, Chua MLK, Turkbey B, Sowalsky AG, Citrin DE. Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence. Clin Cancer Res. 2025 Dec 15;31(24):5211-5224. doi: 10.1158/1078-0432.CCR-25-2186. PMID: 41037000; PMCID: PMC12703358. Read more.

Sousa LG, Edward Bates J, Anand P, Caudell JJ, Colevas AD, Runge CL, Sharon JD, Awan M, Beadle BM, Choe JH, Gidley PW, Harari PM, Henson C, Katzel JA, Lee NY, Mcdowell L, Mell LK, Nader ME, Rudra S, Wang K, Yang G, Yom SS, Wise-Draper TM. Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience. J Natl Cancer Inst. 2025 Dec 4:djaf343. doi: 10.1093/jnci/djaf343. Epub ahead of print. PMID: 41344314. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Head & Neck Society (AHNS) Annual Meeting; Jul 18-22, 2026; Boston, MA

American Radium Society (ARS) Annual Meeting; Apr 30-May 3, 2026; Newport Beach, CA

American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA

American Society of Clinical Oncology (ASCO) GU; Feb 26-28, 2026; San Francisco, CA

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark 

Society for Clinical Trials (SCT); May 17-20, 2026; Phoenix, AZ

Society of Surgical Oncology (SSO) – Annual Meeting; Mar 5-7; Phoenix, AZ

Society of Surgical Oncology (SSO) – Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 17-22, 2026; San Diego, CA; LBA and Clinical Trials Jan 12, 2026, 11:59 pm ET

American Brachytherapy Society (ABS); Jun 17-20; Los Angeles, CA; Due to publications committee Feb 4, 2026; Submission deadline Feb 18, 2026, 6:00 pm CT

American College of Radiology (ACR); May 2-6, 2026; Washington, DC; Due to publications committee Jan 12, 2026; Submission deadline Jan 26, 2026, 11:59 pm ET

American Society of Breast Surgeons (ASBrS); Apr 29-May 3, 2026; Seattle, WA; LBA Jan 9, 2026, 12:00 am PT

American Society of Clinical Oncology (ASCO); May 29-Jun 2, 2026; Chicago, IL; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 11:59 pm ET; LBA Mar 9, 2026, 12:00 pm ET (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; LBA and Clinical Trials Jan 28, 2026, 12:00 pm CT

American Society for Radiation Oncology (ASTRO); Boston, MA; Sep 27-30, 2026; Due to publications committee Feb 10, 2026; Submission deadline Feb 24, 2026, 11:59 pm PT; LBA Apr 20, 2026 (placeholder required)

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; LBA Jan 15, 2026

ESMO (European Society for Medical Oncology) Breast; May 6-8, 2026; Berlin, Germany; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 21:00 CST; LBA Mar 31, 2026, 21:00 CST (placeholder required)

ESMO Gynaecological; Jun 17-19, 2026; Copenhagen, Denmark; Due to publications committee Mar 17, 2026; Submission deadline Mar 31, 2026, 21:00 CET

European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; LBA Apr 8, 2026

International Society for Quality-of-Life Research (ISOQOL); Oct 18-21, 2026; Prague, Czech Republic; Due to publications committee Mar 23, 2026; Submission deadline Apr 6, 2026



Miami Breast Cancer Conference; Mar 5-8, 2026; Miami, FL; Due to publications committee Dec 22, 2025; Submission deadline Jan 5, 2026, 5:00 pm ET